Markus Muttenthaler

In his new ERC project "GUTOCINS" Muttenthaler examines the therapeutic potential of oral oxytocin in abdominal pain. Chronic abdominal pain is a widespread debilitating condition commonly associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). In this project, he will advance a new class of gut-stable peptide analgesics to target abdominal pain at its origin in the gut. This represents a highly innovative treatment strategy with a large safety window due to its gut-specific action and negligible risk of systemic off-target effects.